A Phase 4 interventional study of Evolocumab and Routine Lipid Management in Cardiovascular Disease, Myocardial Infarction and Stroke, sponsored by Amgen. Active, not recruiting at 120 sites in 3 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Amgen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]).
5,372 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.
This study's enrollment of 6,019 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive open-label evolocumab every 2 weeks (Q2W) plus routine lipid management.
Drug: Evolocumab · Drug: Routine Lipid Management
Participants will receive routine lipid management per standard of care (SoC).
Drug: Routine Lipid Management
Evolocumab will be provided as a single-dose, prefilled autoinjector pen (AI/pen) for fixed dose subcutaneous (SC) injection.
Also known as: Repatha, AMG 145
Routine lipid management therapies will be administered at the discretion of the investigator per SoC.
Total (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and all-cause death
Time frame: From Baseline to End of Study (Approximately 3.5 Years)
Percentage Change From Baseline in LDL-C
Percent LDL-C change from baseline to 12 weeks in a subset of approximately 300 randomly selected participants.
Time frame: From Baseline to Week 12
Percentage Change From Baseline in LDL-C
Percent LDL-C change from baseline to 52 weeks in a subset of approximately 300 randomly selected participants.
Time frame: From Baseline to Week 52
Total (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and cardiovascular death
Time frame: From Baseline to End of Study (Approximately 3.5 Years)
Time to the First Occurrence of the Composite of Myocardial Infarction, Ischemic Stroke, any Arterial Revascularization Procedure, and All-Cause Death
Time frame: From Baseline to End of Study (Approximately 3.5 Years)
Total Myocardial Infarctions Events
Time frame: From Baseline to End of Study (Approximately 3.5 Years)
Total Arterial Revascularization Procedures
Time frame: From Baseline to End of Study (Approximately 3.5 Years)
Total Ischemia-driven Coronary Revascularization Procedures
Time frame: From Baseline to End of Study (Approximately 3.5 Years)
Total Ischemic Strokes
Time frame: From Baseline to End of Study (Approximately 3.5 Years)
Time to Cardiovascular Death
Time frame: From Baseline to End of Study (Approximately 3.5 Years)
Time to All-Cause Death
Time frame: From Baseline to End of Study (Approximately 3.5 Years)
Showing the first 100 of 120 sites across 3 countries. Choose a country and city above to see the rest.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Started Oct 2022 (actual). Primary completion is estimated for May 2027, 55 months after the start.
Of 113 phase 4 interventional studies under Cardiovascular Diseases, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 64. This study's planned 55 months is above that.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab